PolarCool Valuation

Is POLAR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of POLAR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate POLAR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate POLAR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for POLAR?

Key metric: As POLAR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for POLAR. This is calculated by dividing POLAR's market cap by their current revenue.
What is POLAR's PS Ratio?
PS Ratio	23.8x
Sales	SEK 1.61m
Market Cap	SEK 38.18m

POLAR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	23.6x
Enterprise Value/EBITDA	-4.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does POLAR's PS Ratio compare to its peers?

The above table shows the PS ratio for POLAR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.3x
CMOTEC B Scandinavian ChemoTech	8x	60.7%	SEK 40.4m
CRBX Carbiotix	10.4x	n/a	SEK 33.8m
ZENI Zenicor Medical Systems	0.8x	n/a	SEK 26.9m
PLUN ProstaLund	1.8x	n/a	SEK 29.7m
POLAR PolarCool	23.8x	n/a	SEK 38.2m

Price-To-Sales vs Peers: POLAR is expensive based on its Price-To-Sales Ratio (23.8x) compared to the peer average (5.3x).

Price to Sales Ratio vs Industry

How does POLAR's PS Ratio compare vs other companies in the SE Medical Equipment Industry?

16 Companies	Price / Sales	Estimated Growth	Market Cap
GETI B Getinge	1.4x	5.7%	US$4.13b
EKTA B Elekta	1.3x	6.0%	US$2.19b
ARJO B Arjo	0.8x	3.7%	US$844.37m
ADDV A ADDvise Group	1.3x	8.5%	US$66.76m

16 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: POLAR is expensive based on its Price-To-Sales Ratio (23.8x) compared to the Swedish Medical Equipment industry average (4.7x).

Price to Sales Ratio vs Fair Ratio

What is POLAR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

POLAR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	23.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate POLAR's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Mentice

SEK 577.9m

Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.

MNTC

SEK 22.60

9.2%

-45.9%

Dignitana

SEK 93.4m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.16

9.4%

-44.5%

Iconovo

SEK 78.0m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 4.90

-4.3%

-44.3%